Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

NCT05286320 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma
Pembrolizumab
Lenvatinib
Stereotactic Body Radiotherapy

Interventions

DRUG: Lenvatinib/Pembrolizumab plus SBRT combinations

Sponsor

National Taiwan University Hospital